文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

做出正确选择的挑战:癌症免疫疗法时代的患者化身。

The challenge of making the right choice: patient avatars in the era of cancer immunotherapies.

机构信息

Group of Inflammatory Carcinogenesis, Institute for Experimental Cancer Research, University Hospital Schleswig-Holstein (UKSH), Kiel University, Kiel, Germany.

Department of Internal Medicine II, University Hospital Center Schleswig-Holstein, Kiel, Germany.

出版信息

Front Immunol. 2023 Aug 10;14:1237565. doi: 10.3389/fimmu.2023.1237565. eCollection 2023.


DOI:10.3389/fimmu.2023.1237565
PMID:37638045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10449253/
Abstract

Immunotherapies are a key therapeutic strategy to fight cancer. Diverse approaches are used to activate tumor-directed immunity and to overcome tumor immune escape. The dynamic interplay between tumor cells and their tumor(immune)microenvironment (T(I)ME) poses a major challenge to create appropriate model systems. However, those model systems are needed to gain novel insights into tumor (immune) biology and a prerequisite to accurately develop and test immunotherapeutic approaches which can be successfully translated into clinical application. Several model systems have been established and advanced into so-called patient avatars to mimic the patient´s tumor biology. All models have their advantages but also disadvantages underscoring the necessity to pay attention in defining the rationale and requirements for which the patient avatar will be used. Here, we briefly outline the current state of tumor model systems used for tumor (immune)biological analysis as well as evaluation of immunotherapeutic agents. Finally, we provide a recommendation for further development to make patient avatars a complementary tool for testing and predicting immunotherapeutic strategies for personalization of tumor therapies.

摘要

免疫疗法是对抗癌症的关键治疗策略。人们采用多种方法来激活针对肿瘤的免疫并克服肿瘤免疫逃逸。肿瘤细胞与其肿瘤(免疫)微环境(T(I)ME)之间的动态相互作用给创建合适的模型系统带来了重大挑战。然而,这些模型系统对于深入了解肿瘤(免疫)生物学以及准确开发和测试可以成功转化为临床应用的免疫治疗方法是必要的。已经建立了几种模型系统,并将其推进到所谓的患者虚拟人,以模拟患者的肿瘤生物学。所有模型都有其优点,但也有缺点,这突出表明有必要注意定义患者虚拟人将被用于的基本原理和要求。在这里,我们简要概述了用于肿瘤(免疫)生物学分析以及评估免疫治疗剂的肿瘤模型系统的当前状态。最后,我们提出了进一步发展的建议,以使患者虚拟人成为测试和预测免疫治疗策略的补充工具,以实现肿瘤治疗的个体化。

相似文献

[1]
The challenge of making the right choice: patient avatars in the era of cancer immunotherapies.

Front Immunol. 2023

[2]
Immuno-oncology-101: overview of major concepts and translational perspectives.

Semin Cancer Biol. 2018-2-8

[3]
3D Tumor Models and Their Use for the Testing of Immunotherapies.

Front Immunol. 2020

[4]
Expression of costimulatory and inhibitory receptors in FoxP3 regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches.

Adv Cancer Res. 2019-6-6

[5]
Bladder Cancer Patient-derived Organoids and Avatars for Personalized Cancer Discovery.

Eur Urol Focus. 2022-5

[6]
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.

Front Immunol. 2020

[7]
Tumor-on-a-chip platforms to study cancer-immune system crosstalk in the era of immunotherapy.

Lab Chip. 2021-1-21

[8]
Organ-on-a-chip models for development of cancer immunotherapies.

Cancer Immunol Immunother. 2023-12

[9]
Patient-derived preclinical models to develop immunotherapies.

Mol Oncol. 2023-7

[10]
Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery.

Curr Pharm Des. 2017

引用本文的文献

[1]
Establishing and Maintaining 3D Organoid Cultures From Human Fallopian Tube Epithelium.

Bio Protoc. 2025-8-20

[2]
Deciphering permissivity of human tumor ecosystems to oncolytic viruses.

Oncogene. 2025-5

[3]
Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy.

Transl Oncol. 2025-1

[4]
Inhibition of ADAM17 increases the cytotoxic effect of cisplatin in cervical spheroids and organoids.

Front Oncol. 2024-9-2

本文引用的文献

[1]
Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens.

Cancer Immunol Immunother. 2023-10

[2]
Human disease models in drug development.

Nat Rev Bioeng. 2023-5-11

[3]
Dual CSF1R inhibition and CD40 activation demonstrates anti-tumor activity in a 3D macrophage- HER2 breast cancer spheroid model.

Front Bioeng Biotechnol. 2023-6-6

[4]
Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice.

Cancers (Basel). 2023-5-30

[5]
Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer.

Front Bioeng Biotechnol. 2023-5-22

[6]
Drug screening at single-organoid resolution via bioprinting and interferometry.

Nat Commun. 2023-6-6

[7]
Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer.

Int J Mol Sci. 2023-5-20

[8]
Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies.

J Immunother Cancer. 2023-5

[9]
Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma.

Front Oncol. 2023-5-3

[10]
The tumor stroma influences immune cell distribution and recruitment in a PDAC-on-a-chip model.

Front Immunol. 2023

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索